Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER vs NEOPHAM 6.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories to prevent catabolism. The mechanism involves intravenous administration bypassing gastrointestinal tract, directly providing essential and non-essential amino acids for anabolism and energy in the form of glucose.
NEOPHAM 6.4% is a sterile, nonpyrogenic, hypertonic solution of amino acids and glycerin used for parenteral nutrition. It provides essential and non-essential amino acids to support protein synthesis and energy metabolism, with glycerin serving as a non-glucose caloric source to reduce hyperglycemia. The amino acids are utilized for tissue repair and growth, while glycerin is metabolized via gluconeogenesis and glycolysis.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day by central line, providing 4.25% amino acids and 10% dextrose. Infusion rate typically 1-2 mL/min initially, adjusted to provide 1-1.5 g/kg/day of amino acids and 3-4 g/kg/day of dextrose.
Intravenous infusion of 6.4% amino acid solution at 0.8-1.5 g/kg/day (equivalent to 12.5-23.4 mL/kg/day) for protein replenishment; typical adult dose 500-1000 mL/day infused at 1-2 mL/min.
None Documented
None Documented
Not applicable as a fixed agent; amino acids have distribution half-life of 15-30 min; dextrose has elimination half-life of 1.5-2.5 hours depending on metabolic state.
Not applicable as a single entity; amino acids have varying half-lives (minutes to hours depending on individual amino acid and metabolic state). Clinical context: continuous infusion used for parenteral nutrition; no terminal elimination half-life defined for the mixture.
Amino acids are metabolized to urea and other nitrogenous wastes; renal excretion of metabolites accounts for >90% of nitrogen elimination, with <5% excreted unchanged in urine. Dextrose is fully metabolized to CO2 and water.
Renal elimination of absorbed amino acids and metabolites; minimal biliary/fecal excretion. >90% of infused amino acids are reincorporated into body protein or metabolized; excess nitrogen excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution